ALEXA WINTER: Open Payments
NPI 1023647872 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,027 in 38 payments from 25 companies in 2025. Trend: 2023 $0 · 2024 $32 · 2025 $1,027
Food & beverage: $827Education: $200
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $114 |
| Daiichi Sankyo Inc. | 4 | $112 |
| Alexion Pharmaceuticals, Inc. | 1 | $100 |
| GENZYME CORPORATION | 2 | $61 |
| Merck Sharp & Dohme LLC | 2 | $59 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| Pharmacosmos Therapeutics Inc. | 2 | $52 |
| Adaptive Biotechnologies Corporation | 2 | $51 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $34 |
Products named: RYBREVANT, SOLIRIS, Enhertu, DATROWAY, MONOFERRIC, clonoSEQ, SARCLISA, VENCLEXTA.
Industry payments across IN — which companies pay providers there.
